Barinthus Biotherapeutics (BRNS) Intangibles (2021 - 2026)

Barinthus Biotherapeutics has reported Intangibles for 6 years, with the latest figure at $13.7 million in Q1 2026.

• For the quarter ending Q1 2026, Intangibles fell 35.4% year-over-year to $13.7 million; the trailing twelve-month figure through Mar 2026 stood at $13.7 million (down 35.4% YoY), and the FY2025 full-year result was $14.3 million, down 34.9% from the prior year.
• Intangibles for Q1 2026 stood at $13.7 million, down from $14.3 million in the prior quarter.
• The five-year high for Intangibles was $30.6 million in Q1 2022, with the low at $13.7 million in Q1 2026.
• Historically, Intangibles has averaged $23.5 million across 5 years, with a median of $24.3 million in 2024.
• Annual changes were most pronounced in 2022 — Intangibles dropped 10.06% — and 2026, when it plunged 35.4%.
• Barinthus Biotherapeutics' Intangibles stood at $28.3 million in 2022, then retreated by 11.18% to $25.1 million in 2023, then retreated by 12.59% to $21.9 million in 2024, then sank by 34.9% to $14.3 million in 2025, then retreated by 4.35% to $13.7 million in 2026.
• The last three Intangibles figures came in at $13.7 million (Q1 2026), $14.3 million (Q4 2025), and $14.9 million (Q3 2025), per Business Quant data.